Pioneering the development of novel immunotherapies for patients with blood cancers and B-cell disorders.

News & Events

HaemaLogiX is delighted to be sharing the results of new pre-clinical data at the European Association of Hematology Congress, EHA2024, taking place this week in Madrid, Spain.

HaemaLogiX presents important new pre-clinical data at EHA2024 in Madrid

14 June 2024

HaemaLogiX welcomes former Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director

19 May 2024

HaemaLogiX's CMDO, Tertia Dex at the Women in BIO and Health – Industry and Networking Forum

HaemaLogiX's CMDO, Tertia Dex to speak at the Women in BIO and Health – Industry and Networking Forum

5 May 2024

Our Team

The HaemaLogiX management team has deep expertise in immunotherapy development and the unique antigens that our treatments target. Our Scientific Advisory Board comprises internationally recognised experts in monoclonal antibodies and haematology.

Team

Our Pipeline

We’re developing a suite of diverse immunotherapies including monoclonal antibodies, CAR-T cells and bispecific antibodies, with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis.

Pipeline

Our Innovation

Our immunotherapies are designed to target and attack two unique antigens expressed on malignant cells – these antigens are not found on normal cells or tissues - making our treatments unlike others on the market.

Technology